A Phase I Dose Escalation Study of Continuous Oral OSI-906 Dosing in Patients With Advanced Solid Tumors.

Trial Profile

A Phase I Dose Escalation Study of Continuous Oral OSI-906 Dosing in Patients With Advanced Solid Tumors.

Completed
Phase of Trial: Phase I

Latest Information Update: 30 Apr 2015

At a glance

  • Drugs Linsitinib (Primary)
  • Indications Colorectal cancer; Solid tumours
  • Focus Adverse reactions
  • Sponsors Astellas Pharma
  • Most Recent Events

    • 17 Apr 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 01 Nov 2011 Company (Astellas Pharma) added as reported by ClinicalTrials.gov.
    • 08 Apr 2011 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top